[1]高杨.生长抑素联合普萘洛尔预防肝硬化并发食管静脉曲张首次破裂出血的疗效[J].医学信息,2020,33(08):163-164.[doi:10.3969/j.issn.1006-1959.2020.08.054]
　GAO Yang,FENG Xiao-jie.Effect of Somatostatin Combined with Propranolol to Prevent Hepatic Cirrhosis Complicated with Esophageal Varices Bleeding[J].Medical Information,2020,33(08):163-164.[doi:10.3969/j.issn.1006-1959.2020.08.054]
点击复制

生长抑素联合普萘洛尔预防肝硬化并发食管静脉曲张首次破裂出血的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
163-164
栏目:
药物与临床
出版日期:
2020-04-15

文章信息/Info

Title:
Effect of Somatostatin Combined with Propranolol to Prevent Hepatic Cirrhosis Complicated with Esophageal Varices Bleeding
文章编号:
1006-1959（2020）08-0163-02
作者:
高杨
（1.北京石景山医院消化内科，北京 100144；2.北京市和平里医院消化科，北京 100013）
Author(s):
GAO Yang; FENG Xiao-jie
(1.Department of Gastroenterology,Beijing Shijingshan Hospital,Beijing 100144,China;2.Department of Gastroenterology,Hepingli Hospital,Beijing 100013,China)
关键词:
肝硬化; 食管静脉曲张破裂出血; 垂体后叶素; 生长抑素; 普萘洛尔
Keywords:
Cirrhosis; Esophageal varices bleeding; Posterior pituitary; Somatostatin; Propranolol
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2020.08.054
文献标志码:
A
摘要:
目的 探讨生长抑素联合普萘洛尔预防肝硬化并发食管静脉曲张首次破裂出血的疗效。方法 选取2018年6月~2019年6月我院收治的肝硬化并发食管静脉曲张首次破裂出血患者96例，采用随机数字表法分为对照组和研究组，每组48例。对照组采用垂体后叶素联合普萘洛尔治疗，研究组采用生长抑素联合普萘洛尔治疗，比较两组临床疗效、治疗前后血流动力学指标[门静脉压（PVP）、门静脉内径（DPV）、门静脉血流速度（VPv)、中心静脉压（CVP）]及不良反应发生情况。结果 研究组治疗总有效率为91.67%，高于对照组的 83.34%（P＜0.05）；治疗后两组PVP、DPV、VPv及CVP均较治疗前好转，且研究组改善程度优于对照组（P＜0.05）；研究组不良反应率为4.17%，低于对照组的15.58%（P＜0.05）。结论 生长抑素联合普萘洛尔在防治肝硬化并发食管静脉曲张所致破裂出血疗效确切，可有效改善血流动力，且安全性高。
Abstract:
Objective To explore the curative effect of somatostatin combined with propranolol in preventing liver cirrhosis complicated with first esophageal varices bleeding.Methods From June 2018 to June 2019, 96 patients with liver cirrhosis complicated with esophageal varices bleeding for the first time were selected in our hospital. Using the random number table method to divided into control group and research group, with 48 cases in each group. The control group was treated with posterior pituitary combined with propranolol, and the research group was treated with somatostatin combined with propranolol. The clinical efficacy, hemodynamic indexes [portal vein pressure (PVP), portal vein inner diameter (DPV), portal vein blood flow velocity (VPv), central venous pressure (CVP)] and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was 91.67%，which was higher than that 83.34% of the control group(P<0.05); PVP, DPV, VPv and CVP in the two groups after treatment were better than before treatment, and study group was better than that in the control group(P<0.05); the adverse reaction rate in the study group was 4.17%, which was lower than that 15.58% of the control group(P<0.05).Conclusion Somatostatin combined with propranolol is effective in preventing and treating liver cirrhosis complicated with esophageal varices bleeding, which can effectively improve blood flow and has high safety.

参考文献/References:

[1]钱静蓉,黄蔚.肝硬化门静脉高压症患者胃动力障碍的多因素分析[J].国际消化病杂志,2018(3):39-41.[2]甘厦,方念,黄神安.内镜套扎术联合生长抑素治疗肝硬化并发食管静脉曲张出血患者临床效果和安全性分析[J].实用肝脏病杂志,2019,22(2):869-873.[3]张育,顾健,朱妍.内科学[M].北京:科学出版社,2016:312-313.[4]姚倩,杨镋灵.血凝酶与生长抑素联合质子泵抑制剂治疗急性上消化道出血的临床效果及对机体炎性反应的影响[J].临床误诊误治,2019(4):119-125.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(08):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Medical Information,2022,35(08):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(08):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(08):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[6]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(08):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[7]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(08):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[8]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Medical Information,2022,35(08):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[9]曾丽妮,吴伟东.多种评分系统评估食管静脉曲张破裂出血患者住院30天预后的临床价值[J].医学信息,2019,32(06):108.[doi:10.3969/j.issn.1006-1959.2019.06.033]
　ZENG Li-ni,WU Wei-dong.Clinical Value of 30-day Hospitalization in Patients with Esophageal Variceal Bleeding Assessed by Multiple Scoring Systems[J].Medical Information,2019,32(08):108.[doi:10.3969/j.issn.1006-1959.2019.06.033]
[10]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]

更新日期/Last Update: 2020-04-15